Eisai Co., Ltd.: Parkinson Disease trials

The registry lists 18 Parkinson Disease studies with Eisai Co., Ltd. as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 2 8Phase 3 7Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South KoreaCompletedNCT05312632Phase 4Results posted
• A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid CopathologyCompletedNCT04764669Phase 2Results posted
• Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor FluctuationsTerminatedNCT01634360Phase 2Results posted
• Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECTTerminatedNCT00566462Phase 2Results posted
• Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor FluctuationsTerminatedNCT00505622Phase 3Results posted
• A Study of E2007 In Patients With Parkinson's DiseaseTerminatedNCT00427011Phase 2Results posted
• Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsCompletedNCT00368108Phase 3Results posted
• A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsTerminatedNCT00360412Phase 3Results posted
• Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsTerminatedNCT00360308Phase 3Results posted
• A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor FluctuationsCompletedNCT00165789Phase 2Results posted
• A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)CompletedNCT05225324
• A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)CompletedNCT04724109
• Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With DementiaCompletedNCT01327859Phase 3
• A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period DyskinesiasCompletedNCT01172379Phase 2
• The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor FluctuationsWithdrawnNCT00451633Phase 2
• The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsCompletedNCT00286897Phase 3
• 2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PDCompletedNCT00209508Phase 2
• The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With DementiaCompletedNCT00165815Phase 3